Freenome, Inc.
FRNM
NASDAQ·Healthcare·Biotechnology·Mkt cap $133.0M
$16.31
▼ -3.49%
P/E
—
Mkt Cap
$133.0M
52-Wk Range
$9.95–$17.18
52-Week Range
$9.95 - $17.18
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 48.1% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Low volatility (beta 0.3).
Growth
No forward estimates available
Value
Valuation data unavailable
Momentum
Hot
+48.1% over 3m
Quality
Solid
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying FRNM right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Dec 2, 2026
Earnings recap unavailable for this period.
Reported EPS · last 4Q
No quarterly earnings data on file.
Wall Street consensus
3 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Guggenheim · Aug 20, 2026
vs Industry
How FRNM stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.